PRINT FRIENDLY

HBA New York presents

Tissue-Agnostic Cancer Drug Development: An Emerging Paradigm Shift?


Date and time
Tuesday, 23 October
  starting at: 05:30PM EST
  through
Tuesday, 23 October
  ending at: 08:30PM EST
Location
Pfizer Inc. Headquarters
235 East 42nd Street
New York, NY 10017 United States

212-733-2323
Event Contact
Van Vu
Competencies
12. Continues to learn, grow and transform
Event sponsor


For many years, the oncology community has desired to treat tumors according to their genetic profile rather than basing treatment solely on the tissue involved. To realize this vision, 'basket' clinical trials are increasingly used to test different tumors in a single trial based on a shared biomarker or mutation. The best example of this, and the first FDA-approved “tissue-agnostic” indication, is Keytruda in MSI-high tumors (approved in 2017). Additional high-profile therapies using the basket trial approach include Loxo Oncology’s LOXO101 in TRK+ tumors, Ignyta’s entrectinib, also in TRK+, and AbbVie’s Rova-T, in DLL3-expressing tumors. The increasing number of tissue-agnostic indications presents several potential challenges and important questions for clinicians, payers, and for industry. Join us for a thought-provoking presentation and discussion on the current landscape for tissue-agnostic oncology products, and implications for stakeholders across the health ecosystem.

Agenda
5:30 - 6:00 PM    Networking
6:00 - 6:10 PM    Welcome and opening remarks
6:10 - 6:15 PM    Speaker introductions
6:15 - 7:15 PM    Panel discussions
7:15 - 7:30 PM    Q&A
7:30 - 8:00 PM    Closing remarks and additional networking

Registration information
Event is open to: HBA members and nonmembers
Online registration deadline: 23 October 2018
Onsite (walk-in) registration: Is allowed
    *To register onsite, please use a smartphone or other device; show your emailed receipt as proof of registration.

This event is nonrefundable.

Featured speakers

Chris  Boshoff
SVP and head of early development and translational oncology
Pfizer Inc.
Geeta  Devgan
Medical director, US medical affairs, Pfizer Oncology
Pfizer Inc.
David  Hyman
Medical oncologist
Memorial Sloan-Kettering Cancer Center
Leigh  Marcus
Pediatric Hematologist/Oncologist, Medical Officer,
FDA
Nitin  Patel
Senior Principal, Consulting Services
IQVIA
Learning Objectives
1. Understand the clinical pipeline for tissue-agnostic approvals, and identify the tipping point when a sufficient number become available and start to influence the industry
2. Describe how a tumor-agnostic approach would affect some of the systems that exist in the management of oncology
3. Discuss the impact of this trend on various stakeholders in the health ecosystem in the near-term (e.g., HCPs, payers, regulatory, industry, etc.)

Registration information

The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.

The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

 Price LevelRegular
Collapse group

Registration: Regular registration

 Member$35.00
 Member - Euro€30.00
 Non-Member$55.00
 Non-Member - Euro€47.00

By registering for this event, you acknowledge that you may be photographed, videotaped and/or audio-taped during the course of the meeting and hereby give permission for your image, voice, or survey comments to be used in education, training, promotion and/or trade and communications media by the Healthcare Businesswomen's Association in any and all media throughout the world, without restriction as to frequency or duration of usage.